6 terminated. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 6 |
| Phase 2 | 1 | Terminated 1 |
Follow Graft Versus Host Disease: new trials by email Literature Review of Graft Versus Host Disease trials Research Report on Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) Itolizumab, EQ001 Placebo - Graft Versus Host Disease, GVHD | Phase 3 | Terminated | Equillium | 158 | 2022-04-29 | 2025-06-17 |
| Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease Brimonidine Tartrate, Placebos - Graft Versus Host Disease, Ocular Surface Disease | Phase 3 | Terminated | Ocugen | 59 | 2018-12-23 | 2022-07-06 |
| A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD GLASSIA, methylprednisolone or equivalent steroid, Albumin - Graft Versus Host Disease | Phase 2 / Phase 3 | Terminated | Baxalta now part of Shire | 1 | 2017-04-26 | 2021-01-13 |
| A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT ATG-F - Allogeneic Haplo-Stem Cell Transplatation (SCT), Graft Versus Host Disease | Phase 3 | Terminated | Hadassah Medical Organization | 50 | 2008-05-01 | 2015-04-21 |
| Alefacept for Prevention of Graft Versus Host Disease (GVHD) Alefacept (AMEVIVE®), control group - Graft Versus Host Disease | Phase 3 | Terminated | Hadassah Medical Organization | 26 | 2006-06-01 | 2015-04-21 |
| Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation cyclosporine, cyclosporine and methotrexate - Leukemia, Lymphoma | Phase 3 | Terminated | Baxalta now part of Shire | 105 | 1997-04-01 | 2021-05-06 |
Graft vs Host Disease (6) · Burkitt Lymphoma (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Immunoblastic (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1)
Immune System Diseases (6) · Bone Marrow Diseases (1) · Chronic Disease (1) · DNA Virus Infections (1) · Disease Attributes (1) · Epstein-Barr Virus Infections (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Herpesviridae Infections (1) · Immunoproliferative Disorders (1) · Infections (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid (1)
Albumins (1) · Alefacept (1) · Brimonidine Tartrate (1) · Control Groups (1) · Cyclosporine (1) · Methotrexate (1) · Methylprednisolone (1) · Serum Albumin, Human (1) · alpha 1-Antitrypsin (1) · itolizumab (1)
Baxalta now part of Shire (2) · Hadassah Medical Organization (2) · Equillium (1) · Ocugen (1)
United States (4) · Israel (3) · Australia (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · New Zealand (1) · Portugal (1) · South Korea (1) · Spain (1)